Dimerix has a new corporate presentation that details some of the scientific and strategic activities for our lead program, DMX-200 for chronic kidney disease (CKD).
The presentation can be downloaded here.
Dimerix Limited or the “Company” (ASX: DXB), a clinical stage biotechnology company today announces results from its 1 for 2 pro-rata non-renounceable Entitlement Offer of fully paid ordinary shares in Dimerix announced on 6 December 2017, opened on 13 December 2017 and closed on 19 January 2018.
View the full release here.
The Dimerix Limited (ASX: DXB) Entitlement Offer or ‘Rights Issue’ to raise $5.5 million is due to close this Friday, 19 January 2018 at 7:00pm AEDT (Sydney time).
Funds raised are important for the commercialisation of DMX-200 across the Chronic Kidney Disease areas of FSGS and Diabetic Nephropathy
An Entitlement and Acceptance form has been mailed to shareholders, and […]
Dimerix Limited announces top-line results from a recent pharmacokinetic (PK) study of an extended release tablet formulation for their DMX-200 program targeting Chronic Kidney Disease (CKD).
The study found a newly formulated extended release tablet of DMX-200 taken twice daily (against three times daily for the previous formulation) increases the duration of release of DMX-200 in […]
CEO Kathy Harrison discusses the exciting data from the Dimerix Phase 2a study in patients with Chronic Kidney Disease (CKD) in this interview from Bio-Europe 2017, Berlin, November 2017.
MELBOURNE, Australia, 14 December 2017: Dimerix Limited (ASX: DXB), a clinical stage biotechnology company is pleased to announce that it has partnered with a leader in predictive diagnostics, Proteomics International (ASX:PIQ), to improve the treatment of Chronic Kidney Disease (CKD).
Proteomics International (PI) has developed PromarkerD, a predictive and diagnostic test for diabetic kidney disease that […]
Dimerix announced last week that it would offer shareholders the opportunity to participate in an Entitlement Offer to raise up to $5.5m. Funds raised would drive the company’s lead drug development program, DMX-200 to its nearest commercial inflection point. In this interview, Boardroom Media’s Co-Founder, Bill Gair interviews Dimerix’s CEO, Kathy Harrison about the company’s […]